Martin Vogelbaum
Chairman en CARA THERAPEUTICS, INC. .
Fortuna: 99 838 $ al 31/03/2024
Perfil
Martin A.
Vogelbaum is the founder of Gloucester Pharmaceuticals, Inc. He currently holds the position of Chief Executive Officer at Ajax Therapeutics, Inc. Additionally, he is the Chairman at CARA Therapeutics, Inc. since 2022.
He is also the Director & Managing Partner at Inning One Ventures LP.
Previously, he served as a Partner at Rho Capital Partners, Inc. starting in 2005.
He also worked as an Advisor at The New York City Investment Fund Manager, Inc. and as a Non-Managing Member at RMV VI LLC.
In terms of former positions, Mr. Vogelbaum served as a Director at Nuvelo, Inc. from 1997 to 2005.
He was also a Director at Middlebrook Pharmaceuticals, Inc. from 2007 to 2010.
From 2010 to 2016, he held the position of Independent Director at Inotek Pharmaceuticals Corp.
He has also served as a Director at Mersana Therapeutics, Inc., AqueSys, Inc., and SARcode Bioscience, Inc. Additionally, he was a Director at Medpace Research, Inc. from 2013 to 2014 and a Director at Nora Therapeutics, Inc. Furthermore, he worked as the Vice President-Business Development at Celgene Corp.
from 2015 to 2017.
He has also held the position of General Partner at Oxford Bioscience Partners and Apple Tree Venture Management LLC.
Moreover, he worked as an Associate at Memorial Sloan Kettering Cancer Center.
Mr. Vogelbaum completed his undergraduate degree at The Trustees of Columbia University in The City of New York.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CARA THERAPEUTICS INC
0.20% | 01/06/2023 | 109 712 ( 0.20% ) | 99 838 $ | 31/03/2024 |
Cargos activos de Martin Vogelbaum
| Empresas | Cargo | Inicio |
|---|---|---|
| CARA THERAPEUTICS, INC. | Chairman | 01/06/2022 |
Ajax Therapeutics, Inc.
 Ajax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ajax Therapeutics, Inc. operates as a biomedical company. The company is headquartered in New York, NY. | Chief Executive Officer | - |
Inning One Ventures LP
 Inning One Ventures LP Investment ManagersFinance Inning One Ventures LP operates as a pooled investment fund firm. The company is headquartered in New York, NY. | Director/Board Member | - |
| RMV VI LLC | Corporate Officer/Principal | - |
Rho Capital Partners, Inc.
 Rho Capital Partners, Inc. Investment ManagersFinance Rho Capital Partners, Inc. (Rho Capital Partners) is a venture capital firm founded in 1981 by Joshua Ruch. The firm is headquartered in New York. | Private Equity Investor | 01/01/2005 |
The New York City Investment Fund Manager, Inc.
 The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Consultant / Advisor | - |
Antiguos cargos conocidos de Martin Vogelbaum.
| Empresas | Cargo | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01/01/2017 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Director/Board Member | 01/01/2016 |
| NEPHROGENEX INC | Director/Board Member | 01/05/2014 |
| ░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formación de Martin Vogelbaum.
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| CARA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 17 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
| Nuvelo, Inc. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
AqueSys, Inc.
 AqueSys, Inc. Medical SpecialtiesHealth Technology AqueSys, Inc. is a clinical-stage medical device company that develops ocular implants that reduce intraocular pressure (IOP) associated with glaucoma. It focuses on commercializing implantable devices that will significantly improve the treatment of glaucoma. The company was founded by Charles E. Larsen in 2006 and is headquartered in Parsippany, NJ | Health Technology |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Health Technology |
Rho Capital Partners, Inc.
Rho Capital Partners, Inc. Investment ManagersFinance Rho Capital Partners, Inc. (Rho Capital Partners) is a venture capital firm founded in 1981 by Joshua Ruch. The firm is headquartered in New York. | Finance |
Medpace Research, Inc.
 Medpace Research, Inc. Medical DistributorsDistribution Services Medpace Research, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Cincinnati, OH. | Distribution Services |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
The New York City Investment Fund Manager, Inc.
The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Finance |
Apple Tree venture Managemnet Llc//vc
 Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Finance |
Nora Therapeutics, Inc.
 Nora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA. | Health Technology |
| RMV VI LLC | |
Inning One Ventures LP
Inning One Ventures LP Investment ManagersFinance Inning One Ventures LP operates as a pooled investment fund firm. The company is headquartered in New York, NY. | Finance |
Ajax Therapeutics, Inc.
Ajax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ajax Therapeutics, Inc. operates as a biomedical company. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Martin Vogelbaum
